Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 4/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31529133 | 0.85 | PAX8 (0.49) | PAX8 | |
| SCHEMBL31529131 | 0.82 | PAX8 (0.38) | PAX8 | |
| SCHEMBL31529181 | 0.78 | PAX8 (0.53) | PAX8ADORA1SMN1; SMN2ADK | |
| SCHEMBL31529311 | 0.77 | PAX8 (0.72) | PAX8SMN1; SMN2CDK2 | |
| SCHEMBL31529146 | 0.76 | PAX8 (0.42) | PAX8ADORA1SMN1; SMN2CA1 | |
| SCHEMBL31529142 | 0.74 | PAX8 (0.47) | PAX8SMN1; SMN2CDK2 | |
| SCHEMBL31529112 | 0.72 | KDM4E (0.30) | — | |
| SCHEMBL31529138 | 0.70 | PAX8 (0.53) | PAX8SMN1; SMN2 | |
| SCHEMBL31529245 | 0.70 | PAX8 (0.41) | PAX8SMN1; SMN2 | |
| SCHEMBL31529348 | 0.66 | PAX8 (0.58) | PAX8SMN1; SMN2ADKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |